



PATENT
Attorney Docket No. UCSD-07017

1642
P#8

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Maurizio Zanetti

Serial No.: 09/788,110

Group No.: Not yet assigned

Filed: 02/15/2001

Examiner: Not yet assigned

Entitled:

**A Universal Vaccine and Method for Treating
Cancer Employing Telomerase Reverse
Transcriptase**

**TRANSMITTAL FOR
INFORMATION DISCLOSURE STATEMENT**

Assistant Commissioner for Patents
Washington, D.C. 20231


RECEIVED

DEC 03 2002

TECH CENTER 1600/2900

CERTIFICATE OF MAILING UNDER 37 CFR § 1.8(a)

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to the: Assistant Commissioner for Patents, Washington, D.C. 20231, on November 27, 2002.

By: 

Cliff Cannon-Cin

Sir or Madam:

Enclosed please find an Information Disclosure Statement, Form PTO-1449 and copy of 68 references for filing in the U.S. Patent and Trademark Office.

In the event a petition is required in order to have this Information Disclosure Statement considered, please consider this a petition therefor.

The Commissioner is hereby authorized to charge any fee or credit overpayment related to this filing to our Deposit Account No. **08-1290**. **An originally executed duplicate of this transmittal is enclosed for this purpose.**


Dated:

11/27/2002

Signed on behalf of:


Maha A. Hamdan
Registration No. 43,655

MEDLEN & CARROLL, LLP
101 Howard Street, Suite 350
San Francisco, California 94105
415.904.6500



PATENT
Attorney Docket No. UCSD-07017

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Maurizio Zanetti

Serial No.:

09/788,110

Group No.: Not yet assigned

Filed:

02/15/2001

Examiner: Not yet assigned

Entitled:

**A Universal Vaccine and Method for Treating
Cancer Employing Telomerase Reverse
Transcriptase**

INFORMATION DISCLOSURE STATEMENT
RECEIVED

Assistant Commissioner for Patents
Washington, D.C. 20231

DEC 03 2002

TECH CENTER 1600/2900

CERTIFICATE OF MAILING UNDER 37 CFR § 1.8(a)

I hereby certify that this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231, on November 27, 2002.

By: 

Cliff Cannon-Cin

Sir or Madam:

The citations listed below, copies attached, may be material to the examination of the above-identified application, and are therefore submitted in compliance with the duty of disclosure defined in 37 C.F.R. §§ 1.56 and 1.97. The Examiner is requested to make these citations of official record in this application.

The following patents are referred to in the body of the specification:

- US Patent No. 4,622,952 issued 11/18/86 to Gordon;
- US Patent No. 5,658,234 issued 8/19/97 to Dunlavy;
- US Patent No. 6,106,829 issued 8/22/00 to He *et al.*;

The following publications are referred to in the body of the specification:

- Mattes *et al.* (1983) "A Pigmentation-associated, Differentiation Antigen of Human Melanoma Defined by a Precipitating Antibody in Human Serum," *Int. J. Cancer* 32:717;
- Tai *et al.* (1983) "Glycoproteins as Differentiation Markers in Human Malignant Melanoma and Melanocytes," *Cancer Res.* 43:2773;

- Thomson *et al.* (1988) "Differentiation Antigens of Melanocytes and Melanoma: Analysis of Melanosome and Cell Surface Markers of Human Pigmented Cells with Monoclonal Antibodies," *J. Invest. Dermatol.* 90:459;
- Zakian (1995) "Telomeres: Beginning to Understand the End," *Science* 270:1601;
- Blackburn and Gall (1978) "A Tandemly Repeated Sequence at the Termini of the Extrachromosomal Ribosomal RNA Genes in *Tetrahymena*," *J. Mol. Biol.* 120:33;
- Oka *et al.* (1980) "Inverted terminal repeat sequence in the macronuclear DNA of *Styloynchia pustulata*," *Gene* 10:301;
- Klobutcher *et al.* (1981) "All gene-sized DNA molecules in four species of hypotrichs have the same terminal sequence and an unusual 3' terminus," *Proc. Natl. Acad. Sci.* 78:3015; and
- Wellinger *et al.* (1993) "Origin Activation and Formation of Single-Strand TG_{1,3} Tails Occur Sequentially in Late S Phase on a Yeast Linear Plasmid," *Mol. Cell. Biol.* 13:4057.

Applicants have become aware of the following printed publication which may be material to the examination of this application and which are listed in alphabetical order:

- US Patent No. 5,635,188 issued 6/3/97 to Bystryn;
- US Patent No. 6,168,946 issued 1/2/01 to Houghton *et al.*;
- Minev *et al.* (2000) "Cytotoxic T cell immunity against telomerase reverse transcriptase in humans," *Proc. Natl. Acad. Sci. USA* 97:4796-4801;
- Vonderheide *et al.* (1999) "The Telomerase Catalytic Subunit Is a Widely Expressed Tumor-Associated Antigen Recognized by Cytotoxic T Lymphocytes," *Immunity* 10:673-679;
- Blackburn (1992) "Telomerases," *Ann. Rev. Biochem.* 61:1139-129;
- Blackburn (1991) "Structure and function of telomeres," *Nature* 350:569-73;
- Greider (1994) "Mammalian teleomere dynamics: healing, fragmentation shortening and stabilization," *Curr. Opin. Genet. Devel.* 4:203-11;

- Counter *et al.* (1992) "Telomere shortening associated with chromosome instability is arrested in immortal cells which express telomerase activity," *EMBO J.* 11:1921-29;
- Buchkovich *et al.* (1996) "Telomerase Regulation during Entry into the Cell Cycle in Normal Human T Cells," *Mol. Biol. Cell* 7:1443-54;
- Weng *et al.* (1996) "Regulated Expression of Telomerase Activity in Human T Lymphocyte Development and Activation," *J. Exp. Med.* 183:2471-9;
- Weng *et al.* (1997) "Telomere lengthening and telomerase activation during human B cell differentiation," *Proc. Natl. Acad. Sci. USA* 94:10827-32;
- Lee *et al.* (1998) "Essential role of mouse telomerase in highly proliferative organs," *Nature* 392:569-74;
- Kim *et al.* (1994) "Specific Association of Human Telomerase Activity with Immortal Cells and Cancer," *Science* 266:2011-5;
- Meyerson *et al.* (1997) "hEST2, the Putative Human Telomerase Catalytic Subunit Gene, is Up-Regulated in Tumor Cells and during Immortalization," *Cell* 90:785-795;
- Bodnar *et al.* (1998) "Extension of Life-Span by Introduction of Telomerase into Normal Human Cells," *Science* 279:349-52;
- Rudolph *et al.* (1999) "Longevity, Stress Response, and Cancer in Aging Telomerase-Deficient Mice," *Cell* 96:701-12;
- Greenberg *et al.* (1999) "Short Dysfunctional Telomeres Impair Tumorigenesis in the INK4a^{Δ2/3} Cancer-Prone Mouse," *Cell* 97:515-25;
- Morales *et al.* (1999) "Absence of cancer-associated changes in human fibroblasts immortalized with telomerase," *Nature Genetics* 21:115-8;
- Hahn *et al.* (1999) "Creation of human tumour cells with defined genetic elements," *Nature* 400:464-8;
- Broccoli *et al.* (1995) "Telomerase activity in normal and malignant hematopoietic cells," *Proc. Natl. Acad. Sci. USA* 92:9082-6;
- Shay *et al.* (1997) "A Survey of Telomerase Activity in Human Cancer," *Eur. J. Cancer* 33:787-91;

- Kim (1997) "Clinical Implications of Telomerase in Cancer," *Eur. J. Cancer* 33:-781-6;
- Nakamura *et al.* (1997) "Telomerase Catalytic Subunit Homologs from Fission Yeast and Human," *Science* 277:955-9;
- Marx (1993) "How p53 Suppresses Cell Growth." *Science* 262:1644-5;
- Disis *et al.* (1997) "HER-2/neu Protein: A Target for Antigen-Specific Immunotherapy of Human Cancer," *Adv. Cancer Res.* 71:343-71;
- Walker *et al.* (1988) "HIV-1 Reverse Transcriptase Is a Target for Cytotoxic T Lymphocytes in Infected Individuals," *Science* 240:64-6;
- Schwartz (1990) "A Cell Culture Model for T Lymphocyte Clonal Anergy," *Science* 248:1349-56;
- Firat *et al.* (1999) "H-2 class I knockout, HLA-12.1-transgenic mice: a versatile animal model for preclinical evaluation of antitumor immunotherapeutic strategies," *Eur. J. Immunol.* 29:3112-21;
- Lee (1990) in *The HLA System*, ed. Lee, J. (Springer-Verlag, NY), pp 141-178;
- Fernandez-Vina *et al.* (1992) "DNA Typing for HLA Class I Alleles: I. Subsets of HLA-A2 and of -A28," *Human Immunol.* 33:163-73;
- Krausa *et al.* (1995) "Genetic polymorphism within HLA-A*02: significant allelic variation revealed in different populations," *Tissue Antigens* 45:223-31;
- Ruppert *et al.* (1993) "Prominent Role of Secondary Anchor Residues in Peptide Binding to HLA-A2.1 Molecules," *Cell.* 74:929-37;
- Parker *et al.* (1994) "Scheme for Ranking Potential HLA-A2 Binding Peptides Based on Independent Binding of Individual Peptide Side-Chains," *J. Immunol.* 152:163-75;
- Vitiello *et al.* (1991) "Analysis of the HLA-restricted Influenza-specific Cytotoxic T Lymphocyte Response in Transgenic Mice Carrying a Chimeric Human-Mouse Class I Major Histocompatibility Complex," *J. Exp. Med.* 173:1007-15;
- Sette *et al.* (1994) "The Relationship Between Class I Binding Affinity and Immunogenicity of Potential Cytotoxic T Cell Epitopes," *J. Immunol.* 153:5586-92;

- van der Burg *et al.* (1996) "Immunogenicity of Peptides Bound to MHC Class I Molecules Depends on the MHC-Peptide Complex Stability," *J. Immunol.* 156:3308-14;
- Sommerfeld *et al.* (1996) "Telomerase Activity: A Prevalent Marker of Malignant Human Prostate Tissue," *Cancer Res.* 56:218-22;
- Hunt *et al.* (1992) "Characterization of Peptides Bound to the Class I MHC Molecule HLA-A2.1 by Mass Spectrometry," *Science* 1261-3;
- Quaranta *et al.* (1982) "A Recurrent Idiotype on Monoclonal Anti-Human Ia Antibodies," *J. Exp. Med.* 156:1551-6;
- Zanetti *et al.* (1993) "Expression of conformationally constrained adhesion peptide in an antibody CDR loop and inhibition of natural killer cell cytotoxic activity by an antibody antigenized with the RGD motif," *EMBO J.* 12:4375-4384;
- Hiyama *et al.* (1995) "Activation of Telomerase in Human Lymphocytes and Hematopoietic Progenitor Cells," *J. Immunol.* 155:3711-15;
- Pascolo *et al.* (1997) "HLA-A2.1-restricted Education and Cytolytic Activity of CD8⁺ T Lymphocytes from β 2 Microglobulin (β 2m) HLA-A2.1 Monochain Transgenic H-2D^b β 2m Double Knockout Mice," *J. Exp. Med.* 185:2043-51;
- Doyle *et al.* (1985) "Markedly Decreased Expression of Class I Histocompatibility Antigens, Protein, and mRNA in Human Small-Cell Lung Cancer," *J. Exp. Med.* 161:1135-51;
- Momburg *et al.* (1986) "Loss of HLA-A,B,C and *De Novo* Expression of HLA-D in Colorectal Cancer," *Int. J. Cancer* 37:179-84;
- Restifo *et al.* (1993) "Identification of Human Cancers Deficient in Antigen Processing," *J. Exp. Med.* 177:265-72;
- Cromme *et al.* (1994) "Loss of Transporter Protein, Encoded by the TAP-1 Gene, is Highly Correlated with Loss of HLA Expression in Cervical Carcinomas," *J. Exp. Med.* 179:335-40;
- Rosenberg *et al.* (1998) "Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma," *Nature Med.* 4:321-27;

- Nestle *et al.* (1998) "Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells," *Nature Med.* 4:328-332;
- Thomson *et al.* (1998) "Delivery of Multiple CD8 Cytotoxic T Cell Epitopes by DNA Vaccination," *J. Immunol.* 160:1717-23;
- Sykulev *et al.* (1996) "Evidence that a Single Peptide-MHC Complex on a Target Cell Can Elicit a Cytolytic T Cell Response," *Immunity* 4:565-71;
- Morgan *et al.* (1998) "Activation of Low Avidity CTL Specific for a Self Epitope Results in Tumor Rejection But Not Autoimmunity," *J. Immunol.* 160:643-51;
- Overwijk *et al.* (1999) "Vaccination with a recombinant vaccinia virus encoding a "self" antigen induces autoimmune vitiligo and tumor cell destruction in mice: Requirement for CD4⁺ T lymphocytes," *Proc. Natl. Acad. Sci. USA* 96:2982-7;
- Hu *et al.* (1993) "An Evaluation of the Potential to Use Tumor-associated Antigens as Targets for Antitumor T Cell Therapy Using Transgenic Mice Expressing a Retroviral Tumor Antigen in Normal Lymphoid Tissues," *J. Exp. Med.* 177:1681-90;
- Uyttenhove *et al.* (1997) "The Expression of Mouse Gene *P1A* In Testis Does Not Prevent Safe Induction of Cytolytic T Cells Against a P1A-Encoded Tumor Antigen," *Int. J. Cancer* 70:349-56;
- Falk *et al.* (1991) "Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules," *Nature* 351:290-6;
- Rotzschke *et al.* (1990) "Isolation and analysis of naturally processed viral peptides as recognized by cytotoxic T cells," *Nature* 348:252-254; and
- Schumacher *et al.* (1991) "Peptide selection by MHC class I molecules," *Nature* 350:703-6.

This Information Disclosure Statement under 37 C.F.R. §§ 1.56 and 1.97 is not to be construed as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that any one or more of these citations constitutes prior art.

Signed on behalf of:

Dated: November 27, 2002



Maha A. Hamdan
Registration No. 43,655

MEDLEN & CARROLL, LLP
101 Howard Street, Suite 350
San Francisco, California 94105
415.904.6500

FORM PTO-1449 (Modified)		U.S. Department of Commerce Patent and Trademark Office		Attorney Docket No.: UCSD-07017	Serial No.: 09/788,110	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use Several Sheets If Necessary)				Applicant: Maurizio Zanetti		
				Filing Date: 02/15/01		Group Art Unit:
(37 CFR § 1.98(b))				U.S. PATENT DOCUMENTS		

Examiner Initials	Cite No.	Serial / Patent Number	Issue Date	Applicant / Patentee	Class	Subclass	Filing Date
	1	4,622,952	11/18/86	Gordon			
	2	5,658,234	8/19/97	Dunlavy			
	3	6,106,829	8/22/00	He <i>et al.</i>			
	4	6,168,946	1/2/01	Houghton <i>et al.</i>			
	5	5,635,188	6/3/97	Bystryn			

RECEIVED

DEC 02 2002

TECH CENTER 1600/2000

OTHER DOCUMENTS (Including Author, Title, Date, Relevant Pages, Place of Publication)

6 ✓	Mattes <i>et al.</i> (1983) "A Pigmentation-associated, Differentiation Antigen of Human Melanoma Defined by a Precipitating Antibody in Human Serum," <i>Int. J. Cancer</i> 32:717
7 ✓	Tai <i>et al.</i> (1983) "Glycoproteins as Differentiation Markers in Human Malignant Melanoma and Melanocytes," <i>Cancer Res.</i> 43:2773
8 ✓	Thomson <i>et al.</i> (1988) "Differentiation Antigens of Melanocytes and Melanoma: Analysis of Melanosome and Cell Surface Markers of Human Pigmented Cells with Monoclonal Antibodies," <i>J. Invest. Dermatol.</i> 90:459
9 ✓	Zakian (1995) "Telomeres: Beginning to Understand the End," <i>Science</i> 270:1601
10 ✓	Blackburn and Gall (1978) "A Tandemly Repeated Sequence at the Termini of the Extrachromosomal Ribosomal RNA Genes in <i>Tetrahymena</i> ," <i>J. Mol. Biol.</i> 120:33
11 ✓	Öka <i>et al.</i> (1980) "Inverted terminal repeat sequence in the macronuclear DNA of <i>Styloynchia pustulata</i> ," <i>Gene</i> 10:301
12 ✓	Klobutcher <i>et al.</i> (1981) "All gene-sized DNA molecules in four species of hypotrichs have the same terminal sequence and an unusual 3' terminus," <i>Proc. Natl. Acad. Sci.</i> 78:3015
13 ✓	Wellinger <i>et al.</i> (1993) "Origin Activation and Formation of Single-Strand TG _{1,3} Tails Occur Sequentially in Late S Phase on a Yeast Linear Plasmid," <i>Mol. Cell. Biol.</i> 13:4057
14 ✓	Minev <i>et al.</i> (2000) "Cytotoxic T cell immunity against telomerase reverse transcriptase in humans," <i>Proc. Natl. Acad. Sci. USA</i> 97:4796-4801
15 ✓	Vonderheide <i>et al.</i> (1999) "The Telomerase Catalytic Subunit Is a Widely Expressed Tumor-Associated Antigen Recognized by Cytotoxic T Lymphocytes," <i>Immunity</i> 10:673-679
16 ✓	Blackburn (1992) "Telomerases," <i>Ann. Rev. Biochem.</i> 61:1139-129
17 ✓	Blackburn (1991) "Structure and function of telomeres," <i>Nature</i> 350:569-73
18 ✓	Greider (1994) "Mammalian telomere dynamics: healing, fragmentation shortening and stabilization," <i>Curr. Opin. Genet. Devel.</i> 4:203-11
19 ✓	Counter <i>et al.</i> (1992) "Telomere shortening associated with chromosome instability is arrested in immortal cells which express telomerase activity," <i>EMBO J.</i> 11:1921-29
20 ✓	Buchkovich <i>et al.</i> (1996) "Telomerase Regulation during Entry into the Cell Cycle in Normal Human T Cells," <i>Mol. Biol. Cell</i> 7:1443-54
21 ✓	Weng <i>et al.</i> (1996) "Regulated Expression of Telomerase Activity in Human T Lymphocyte Development and Activation," <i>J. Exp. Med.</i> 183:2471-9
22 ✓	Weng <i>et al.</i> (1997) "Telomere lengthening and telomerase activation during human B cell differentiation," <i>Proc. Natl. Acad. Sci. USA</i> 94:10827-32
23 ✓	Lee <i>et al.</i> (1998) "Essential role of mouse telomerase in highly proliferative organs," <i>Nature</i> 392:569-74
24 ✓	Kim <i>et al.</i> (1994) "Specific Association of Human Telomerase Activity with Immortal Cells and Cancer," <i>Science</i> 266:2011-5
25 ✓	Meyerson <i>et al.</i> (1997) "hEST2, the Putative Human Telomerase Catalytic Subunit Gene, is Up-Regulated in Tumor Cells and during Immortalization," <i>Cell</i> 90:785-795

Examiner:

Date Considered:

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (Modified)		U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No.: UCSD-02424	Serial No.: 08/723,052
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use Several Sheets If Necessary) (37 CFR § 1.98(b))		Applicant: Mario Chojkier <i>et al.</i>		
		Filing Date: 09/30/96	Group Art Unit:	
OTHER DOCUMENTS (Including Author, Title, Date, Relevant Pages, Place of Publication)				
26	Bodnar <i>et al.</i> (1998) "Extension of Life-Span by Introduction of Telomerase into Normal Human Cells," <i>Science</i> 279:349-52			
27	Rudolph <i>et al.</i> (1999) "Longevity, Stress Response, and Cancer in Aging Telomerase-Deficient Mice," <i>Cell</i> 96:701-12			
28	Greenberg <i>et al.</i> (1999) "Short Dysfunctional Telomeres Impair Tumorigenesis in the INK4a ^{Δ2/3} Cancer-Prone Mouse," <i>Cell</i> 97:515-25			
29	Morales <i>et al.</i> (1999) "Absence of cancer-associated changes in human fibroblasts immortalized with telomerase," <i>Nature Genetics</i> 21:115-8			
30	Hahn <i>et al.</i> (1999) "Creation of human tumour cells with defined genetic elements," <i>Nature</i> 400:464-8			
31	Broccoli <i>et al.</i> (1995) "Telomerase activity in normal and malignant hematopoietic cells," <i>Proc. Natl. Acad. Sci. USA</i> 92:9082-6			
32	Shay <i>et al.</i> (1997) "A Survey of Telomerase Activity in Human Cancer," <i>Eur. J. Cancer</i> 33:787-91			
33	Kim (1997) "Clinical Implications of Telomerase in Cancer," <i>Eur. J. Cancer</i> 33:-781-6			
34	Nakamura <i>et al.</i> (1997) "Telomerase Catalytic Subunit Homologs from Fission Yeast and Human," <i>Science</i> 277:955-9			
35	Marx (1993) "How p53 Suppresses Cell Growth." <i>Science</i> 262:1644-5			
36	Disis <i>et al.</i> (1997) "HER-2/neu Protein: A Target for Antigen-Specific Immunotherapy of Human Cancer," <i>Adv. Cancer Res.</i> 71:343-71			
37	Walker <i>et al.</i> (1988) "HIV-1 Reverse Transcriptase Is a Target for Cytotoxic T Lymphocytes in Infected Individuals," <i>Science</i> 240:64-6			
38	Schwartz (1990) "A Cell Culture Model for T Lymphocyte Clonal Anergy," <i>Science</i> 248:1349-56			
39	Firat <i>et al.</i> (1999) "H-2 class I knockout, HLA-12.1-transgenic mice: a versatile animal model for preclinical evaluation of antitumor immunotherapeutic strategies," <i>Eur. J. Immunol.</i> 29:3112-21			
40	Lee (1990) in <i>The HLA System</i> , ed. Lee, J. (Springer-Verlag, NY), pp 141-178			
41	Fernandez-Vina <i>et al.</i> (1992) "DNA Typing for HLA Class I Alleles, I. Subsets of HLA-A2 and of -A28," <i>Human Immunol.</i> 33:163-73			
42	Krausa <i>et al.</i> (1995) "Genetic polymorphism within HLA-A*02: significant allelic variation revealed in different populations," <i>Tissue Antigens</i> 45:223-31;			
43	Ruppert <i>et al.</i> (1993) "Prominent Role of Secondary Anchor Residues in Peptide Binding to HLA-A2.1 Molecules," <i>Cell</i> 74:929-37;			
44	Parker <i>et al.</i> (1994) "Scheme for Ranking Potential HLA-A2 Binding Peptides Based on Independent Binding of Individual Peptide Side-Chains," <i>J. Immunol.</i> 152:163-75			
45	Vitiello <i>et al.</i> (1991) "Analysis of the HLA-restricted Influenza-specific Cytotoxic T Lymphocyte Response in Transgenic Mice Carrying a Chimeric Human-Mouse Class I Major Histocompatibility Complex," <i>J. Exp. Med.</i> 173:1007-15			
46	Sette <i>et al.</i> (1994) "The Relationship Between Class I Binding Affinity and Immunogenicity of Potential Cytotoxic T Cell Epitopes," <i>J. Immunol.</i> 153:5586-92			
47	van der Burg <i>et al.</i> (1996) "Immunogenicity of Peptides Bound to MHC Class I Molecules Depends on the MHC-Peptide Complex Stability," <i>J. Immunol.</i> 156:3308-14			
48	Sommerfeld <i>et al.</i> (1996) "Telomerase Activity: A Prevalent Marker of Malignant Human Prostate Tissue," <i>Cancer Res.</i> 56:218-22			
49	Hunt <i>et al.</i> (1992) "Characterization of Peptides Bound to the Class I MHC Molecule HLA-A2.1 by Mass Spectrometry," <i>Science</i> 1261-3			
50	Quaranta <i>et al.</i> (1982) "A Recurrent Idiotype on Monoclonal Anti-Human Ia Antibodies," <i>J. Exp. Med.</i> 156:1551-6			
51	Zanetti <i>et al.</i> (1993) "Expression of conformationally constrained adhesion peptide in an antibody CDR loop and inhibition of natural killer cell cytotoxic activity by an antibody antigenized with the RGD motif," <i>EMBO J.</i> 12:4375-4384			
52	Hiyama <i>et al.</i> (1995) "Activation of Telomerase in Human Lymphocytes and Hematopoietic Progenitor Cells," <i>J. Immunol.</i> 155:3711-15			
53	Pascolo <i>et al.</i> (1997) "HLA-A2.1-restricted Education and Cytolytic Activity of CD8 ⁺ T Lymphocytes from $\beta 2$ Microglobulin ($\beta 2m$) HLA-A2.1 Monochain Transgenic H-2D ^b $\beta 2m$ Double Knockout Mice," <i>J. Exp. Med.</i> 185:2043-51			
54	Doyle <i>et al.</i> (1985) "Markedly Decreased Expression of Class I Histocompatibility Antigens, Protein, and mRNA in Human Small-Cell Lung Cancer," <i>J. Exp. Med.</i> 161:1135-51			
Examiner:		Date Considered:		
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.				

RECEIVED

DEC 03 2002

TECH CENTER 1000/2900

FORM PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No.: UCSD-02424	Serial No.: 08/723,052
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use Several Sheets If Necessary)		Applicant: Mario Chojkier <i>et al.</i>	
(37 CFR § 1.98(b))		Filing Date: 09/30/96	Group Art Unit:

OTHER DOCUMENTS (Including Author, Title, Date, Relevant Pages, Place of Publication)

55 ✓ Momburg *et al.* (1986) "Loss of HLA-A,B,C and *De Novo* Expression of HLA-D in Colorectal Cancer," *Int. J. Cancer* 37:179-84

56 ✓ Restifo *et al.* (1993) "Identification of Human Cancers Deficient in Antigen Processing," *J. Exp. Med.* 177:16-71

57 ✓ Cromme *et al.* (1994) "Loss of Transporter Protein, Encoded by the TAP-1 Gene, is Highly Correlated with Loss of HLA Expression in Cervical Carcinomas," *J. Exp. Med.* 179:335-40

58 ✓ Rosenberg *et al.* (1998) "Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma," *Nature Med.* 4:321-27

59 ✓ Nestle *et al.* (1998) "Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells," *Nature Med.* 4:328-332

60 ✓ Thomson *et al.* (1998) "Delivery of Multiple CD8 Cytotoxic T Cell Epitopes by DNA Vaccination," *J. Immunol.* 160:1717-23

61 ✓ Sykulev *et al.* (1996) "Evidence that a Single Peptide-MHC Complex on a Target Cell Can Elicit a Cytolytic T Cell Response," *Immunity* 4:565-71

62 ✓ Morgan *et al.* (1998) "Activation of Low Avidity CTL Specific for a Self Epitope Results in Tumor Rejection But Not Autoimmunity," *J. Immunol.* 160:643-51

63 ✓ Overwijk *et al.* (1999) "Vaccination with a recombinant vaccinia virus encoding a "self" antigen induces autoimmune vitiligo and tumor cell destruction in mice: Requirement for CD4⁺ T lymphocytes," *Proc. Natl. Acad. Sci. USA* 96:2982-7

64 ✓ Hu *et al.* (1993) "An Evaluation of the Potential to Use Tumor-associated Antigens as Targets for Antitumor T Cell Therapy Using Transgenic Mice Expressing a Retroviral Tumor Antigen in Normal Lymphoid Tissues," *J. Exp. Med.* 177:1681-90

65 ✓ Uyttenhove *et al.* (1997) "The Expression of Mouse Gene PIA In Testis Does Not Prevent Safe Induction of Cytolytic T Cells Against a PIA-Encoded Tumor Antigen," *Int. J. Cancer* 70:349-56

66 ✓ Falk *et al.* (1991) "Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules," *Nature* 351:290-6

67 ✓ Rotzschke *et al.* (1990) "Isolation and analysis of naturally processed viral peptides as recognized by cytotoxic T cells," *Nature* 348:252-254

68 ✓ Schumacher *et al.* (1991) "Peptide selection by MHC class I molecules," *Nature* 350:703-6

RECEIVED

DEC 03 2002
TECH CENTER 1800/2000

Examiner:

Date Considered:

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

